147962-41-2

Basic information

• Product Name: PropylsulfaMide
• Synonyms: N-PropylsulfaMide;PropylsulfaMide;N-Propyl-sulfaMide potassiuM;SulfaMide, N-propyl-;SulfaMide, propyl-;N-(1-propyl)sulfamide;Propylamino sulfonamide;Macitentan Intermediate 4
• CAS NO: 147962-41-2
• Molecular Formula: C₃H₁₀N₂O₂S
• Molecular Weight: 138.1887
• Mol File: 147962-41-2.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 249.0±23.0 °C(Predicted)
• Appearance: /
• Density: 1.238±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.06±0.60(Predicted)
• CAS DataBase Reference: PropylsulfaMide(CAS DataBase Reference)
• NIST Chemistry Reference: PropylsulfaMide(147962-41-2)
• EPA Substance Registry System: PropylsulfaMide(147962-41-2)

Safety Data

• Hazardous Substances Data: 147962-41-2(Hazardous Substances Data)

Usage

General Description

Propylsulfamide is a chemical compound that is primarily used in the field of medicine, specifically in the production of certain types of drugs. It is a derivative of sulfamide and features a unique composition that includes carbon, hydrogen, nitrogen, oxygen, and sulfur atoms. Notably, this compound plays a vital role in the formulation of medicines such as anti-convulsants and diuretics. Additionally, it serves an important function in the production of sulfa drugs, which are commonly used to treat bacterial infections. However, similar to other chemical compounds, it should be handled carefully due to potential health risks associated with improper exposure.

Upstream product

• 10305-42-7 N-propylsulfamoyl chloride 
• 107-10-8 propylamine 
• 1189-71-5 isocyanate de chlorosulfonyle 
• 1393813-40-5 tert-butyl (1-propyl)aminosulfonylcarbamate 

Downstream Products

• 1393813-42-7 N-5-(4-bromophenyl)-6-chloro-4-pyrimidinyl-N‘-propylsulfamide 

Relevant articles and documents

PYRIMIDINE SULFAMIDE DERIVATIVE AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF

Disclosed are a series of pyrimidine sulfamide compounds and applications thereof in preparing a drug for a disease related to an ETA receptor antagonist. In particular, disclosed is a derived compound represented by formula (I) or a tautomer or pharmaceutically acceptable composition thereof.

Synthesis and antitumor evaluation of novel sulfonylcycloureas derived from nitrogen mustard

A new series of sulfonylcycloureas derivatives have been synthesized and evaluated in vitro for their antitumor activity against four cancer cell lines (A431, Jurkat, U266, and K562). These compounds were prepared by the condensation of several sulfonamides (2am) with ethyl bis(2-chloroethyl)carbamate (1a). The relative cytotoxicity of these new derivatives in comparison to chlorambucil is reported.

PROCESS FOR PREPARING A PYRIMIDINE INTERMEDIATE

The present invention relates to a process for preparing a pyrimidine intermediate, namely the compound of formula I-2 or a salt thereof. Said compound of formula I-2 or its salt can be used to prepare macitentan. Macitentan (chemical names: N-[5-(4-bromophenyl)-6-[2-[(5-bromo- 2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl] -N'-propylsulfamide or N-[5-(4-bromophenyl)- 6- {2- [(5 -bromopyrimidin-2-yl)oxy] ethoxy } pyrimidin-4-yl] -N'-propylsulfuric diamide) is an endothelin receptor antagonist that has notably been approved by the US Food and Drug Administration and the European Commission for the treatment of pulmonary arterial hypertension. It has been first disclosed in WO 02/053557. The last step of one of the potential preparation routes described in WO 02/053557, called Possibility A and Possibility B , can be summarised as shown in Scheme Al hereafter.